This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Company News for Jul 24, 2024
by Zacks Equity Research
Companies in The News Are: DHR, GM, PM, ARE
Danaher (DHR) Q2 Earnings Beat, Biotechnology Sales Dip Y/Y
by Zacks Equity Research
Danaher's (DHR) second-quarter earnings and revenues surpass estimates. However, the company's performance reflects a decrease in core sales in the Biotechnology segment.
Here's What Key Metrics Tell Us About Danaher (DHR) Q2 Earnings
by Zacks Equity Research
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Danaher (DHR) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Danaher (DHR) delivered earnings and revenue surprises of 9.55% and 2.78%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3M (MMM) Rises 13.4% in 3 Months: How Should You Play the Stock?
by Avisekh Bhattacharjee
3M (MMM) is making strides in the diversified technology services market, which makes the stock worth a watch amid certain headwinds.
Danaher (DHR) Gears Up to Post Q2 Earnings: What to Expect
by Zacks Equity Research
Danaher's (DHR) second-quarter earnings are likely to be aided by strength in the Diagnostics and Life Sciences segment.
Danaher (DHR) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Danaher (DHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Danaher (DHR) Stock Outpacing Its Conglomerates Peers This Year?
by Zacks Equity Research
Here is how Danaher (DHR) and Honeywell International Inc. (HON) have performed compared to their sector so far this year.
Is Invesco Water Resources ETF (PHO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PHO
The Zacks Analyst Blog Highlights Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals and Oil-Dri
by Zacks Equity Research
Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals and Oil-Dri are part of the Zacks top Analyst Blog.
Top Analyst Reports for Danaher, Morgan Stanley & Pfizer
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Morgan Stanley (MS) and Pfizer Inc. (PFE), as well as two micro-cap stocks, Elite Pharmaceuticals, Inc. (ELTP) and Oil-Dri Corporation of America (ODC).
Should You Invest in the Invesco Global Water ETF (PIO)?
by Zacks Equity Research
Sector ETF report for PIO
Should You Invest in the Invesco Water Resources ETF (PHO)?
by Zacks Equity Research
Sector ETF report for PHO
The Zacks Analyst Blog Highlights Walmart, Exxon Mobil, Danaher and GSI Technology
by Zacks Equity Research
Walmart, Exxon Mobil, Danaher and GSI Technology are part of the Zacks top Analyst Blog.
Top Stock Reports for Walmart, Exxon Mobil & Danaher
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), Exxon Mobil Corporation (XOM) and Danaher Corporation (DHR), as well as a micro-cap stock GSI Technology, Inc. (GSIT).
Here's Why Hold Strategy Is Apt for Danaher (DHR) Stock Now
by Zacks Equity Research
Strength in the Life Sciences segment augurs well for Danaher (DHR). The company's measures to reward its shareholders are promising.
Why Is Danaher (DHR) Up 6.7% Since Last Earnings Report?
by Zacks Equity Research
Danaher (DHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: UnitedHealth, Danaher, Abbott and Ark Restaurants
by Zacks Equity Research
UnitedHealth, Danaher, Abbott and Ark Restaurants are included in this Analyst Blog.
Top Stock Reports for UnitedHealth, Danaher & Abbott
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Danaher Corporation (DHR) and Abbott Laboratories (ABT), as well as a micro-cap stock Ark Restaurants Corp. (ARKR).
Danaher (DHR) Rides on Business Strength Amid Headwinds
by Zacks Equity Research
Danaher (DHR) gains from strength in academic and applied markets, Abcam buyout and pro-investor policies. However, softness in its Biotechnology unit is concerning.
Danaher Corporation (DHR) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Danaher (DHR) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Markel (MKL) Q1 Earnings, Revenues Miss Estimates, Rise Y/Y
by Zacks Equity Research
Markel (MKL) first-quarter results reflect improved earned premiums and increased net investment income.
Honeywell (HON) Q1 Earnings Beat, Aerospace Sales Rise Y/Y
by Zacks Equity Research
Honeywell's (HON) first-quarter 2024 revenues increase approximately 3%, driven by strong momentum in the Aerospace Technologies segment.
The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power
by Zacks Equity Research
Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power are part of the Zacks top Analyst Blog.